232 related articles for article (PubMed ID: 32548668)
1. Tucatinib: First Approval.
Lee A
Drugs; 2020 Jul; 80(10):1033-1038. PubMed ID: 32548668
[TBL] [Abstract][Full Text] [Related]
2. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
3. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
4. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].
Bonnemort J; Bellesoeur A
Bull Cancer; 2021; 108(7-8):673-675. PubMed ID: 34172272
[No Abstract] [Full Text] [Related]
5. FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
Shah M; Wedam S; Cheng J; Fiero MH; Xia H; Li F; Fan J; Zhang X; Yu J; Song P; Chen W; Ricks TK; Chen XH; Goldberg KB; Gong Y; Pierce WF; Tang S; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2021 Mar; 27(5):1220-1226. PubMed ID: 33055172
[TBL] [Abstract][Full Text] [Related]
6. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.
Kulukian A; Lee P; Taylor J; Rosler R; de Vries P; Watson D; Forero-Torres A; Peterson S
Mol Cancer Ther; 2020 Apr; 19(4):976-987. PubMed ID: 32241871
[TBL] [Abstract][Full Text] [Related]
8. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
9. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Smith AE; Ferraro E; Safonov A; Morales CB; Lahuerta EJA; Li Q; Kulick A; Ross D; Solit DB; de Stanchina E; Reis-Filho J; Rosen N; Arribas J; Razavi P; Chandarlapaty S
Nat Commun; 2021 Nov; 12(1):6667. PubMed ID: 34795269
[TBL] [Abstract][Full Text] [Related]
10. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
Cordero A; Ramsey MD; Kanojia D; Fares J; Petrosyan E; Schwartz CW; Burga R; Zhang P; Rashidi A; Castro B; Xiao T; Lee-Chang C; Miska J; Balyasnikova IV; Ahmed AU; Lesniak MS
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34969858
[TBL] [Abstract][Full Text] [Related]
11. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
O'Brien NA; Huang HKT; McDermott MSJ; Madrid AM; Luo T; Ayala R; Issakhanian S; Gong KW; Lu M; Zhang J; Slamon DJ
Mol Cancer Ther; 2022 May; 21(5):751-761. PubMed ID: 35417017
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer.
Sirhan Z; Thyagarajan A; Sahu RP
Mil Med Res; 2022 Jul; 9(1):39. PubMed ID: 35820970
[TBL] [Abstract][Full Text] [Related]
13. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
15. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.
Corti C; Criscitiello C
ESMO Open; 2021 Apr; 6(2):100063. PubMed ID: 33676293
[No Abstract] [Full Text] [Related]
16. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
17. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
Ahn D; Walden D; Bekaii-Saab T
Expert Opin Investig Drugs; 2022 May; 31(5):437-441. PubMed ID: 35289234
[TBL] [Abstract][Full Text] [Related]
18. Development and Challenges of the Discovery of HER2 Inhibitors.
Sun ZG; Zhao LH; Li ZN; Zhu HL
Mini Rev Med Chem; 2020; 20(20):2123-2134. PubMed ID: 32727326
[TBL] [Abstract][Full Text] [Related]
19. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O; Leone JP; Li T; Tan-Wasielewski Z; Trippa L; Barry WT; Younger J; Lawler E; Walker L; Freedman RA; Tolaney SM; Krop I; Winer EP; Lin NU
Ann Oncol; 2020 Sep; 31(9):1231-1239. PubMed ID: 32461105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
